UBS Group’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.69M | Sell |
444,400
-396,558
| -47% | -$5.43M | ﹤0.01% | 3738 |
|
|
2026
Q1 | $10.5M | Sell |
840,958
-94,521
| -10% | -$1.27M | ﹤0.01% | 3281 |
|
|
2025
Q4 | $11.8M | Sell |
935,479
-510,322
| -35% | -$5.84M | ﹤0.01% | 3126 |
|
|
2025
Q3 | $14.5M | Sell |
1,445,801
-136,949
| -9% | -$1.23M | ﹤0.01% | 2917 |
|
|
2025
Q2 | $12.8M | Sell |
1,582,750
-229,625
| -13% | -$1.73M | ﹤0.01% | 2831 |
|
|
2025
Q1 | $15.2M | Buy |
1,812,375
+146,850
| +9% | +$1.23M | ﹤0.01% | 2616 |
|
|
2024
Q4 | $13.2M | Sell |
1,665,525
-20,107,524
| -92% | -$169M | ﹤0.01% | 2763 |
|
|
2024
Q3 | $181M | Sell |
21,773,049
-76,474
| -0.4% | -$598K | 0.04% | 452 |
|
|
2024
Q2 | $139M | Buy |
21,849,523
+21,671,365
| +12,164% | +$138M | 0.03% | 492 |
|
|
2024
Q1 | $1.08M | Buy |
178,158
+3,931
| +2% | +$22.2K | ﹤0.01% | 4541 |
|
|
2023
Q4 | $1.06M | Buy |
174,227
+105,809
| +155% | +$471K | ﹤0.01% | 4451 |
|
|
2023
Q3 | $289K | Buy |
68,418
+56,529
| +475% | +$211K | ﹤0.01% | 5083 |
|
|
2023
Q2 | $36.9K | Buy |
11,889
+6,644
| +127% | +$14.2K | ﹤0.01% | 6628 |
|
|
2023
Q1 | $7.29K | Sell |
5,245
-13,738
| -72% | -$27.4K | ﹤0.01% | 7824 |
|
|
2022
Q4 | $37.8K | Sell |
18,983
-7,592
| -29% | -$17K | ﹤0.01% | 7022 |
|
|
2022
Q3 | $54K | Buy |
26,575
+15,430
| +138% | +$43.2K | ﹤0.01% | 6274 |
|
|
2022
Q2 | $35K | Sell |
11,145
-1,193
| -10% | -$4.32K | ﹤0.01% | 6210 |
|
|
2022
Q1 | $51K | Sell |
12,338
-24,982
| -67% | -$111K | ﹤0.01% | 6471 |
|
|
2021
Q4 | $178K | Buy |
37,320
+26,320
| +239% | +$131K | ﹤0.01% | 5798 |
|
|
2021
Q3 | $59K | Sell |
11,000
-9,242
| -46% | -$46.5K | ﹤0.01% | 6201 |
|
|
2021
Q2 | $103K | Buy |
20,242
+9,242
| +84% | +$52.5K | ﹤0.01% | 5853 |
|
|
2021
Q1 | $74K | Sell |
11,000
-43,049
| -80% | -$239K | ﹤0.01% | 6190 |
|
|
2020
Q4 | $247K | Buy |
54,049
+11,786
| +28% | +$52.2K | ﹤0.01% | 5103 |
|
|
2020
Q3 | $164K | Sell |
42,263
-39,183
| -48% | -$168K | ﹤0.01% | 4913 |
|
|
2020
Q2 | $387K | Buy |
81,446
+69,106
| +560% | +$285K | ﹤0.01% | 4337 |
|
|
2020
Q1 | $43K | Buy |
12,340
+6,840
| +124% | +$29K | ﹤0.01% | 5945 |
|
|
2019
Q4 | $27K | Sell |
5,500
-2,128
| -28% | -$7.4K | ﹤0.01% | 6701 |
|
|
2019
Q3 | $22K | Sell |
7,628
-15,645
| -67% | -$54.6K | ﹤0.01% | 6674 |
|
|
2019
Q2 | $167K | Sell |
23,273
-18,154
| -44% | -$186K | ﹤0.01% | 5032 |
|
|
2019
Q1 | $586K | Sell |
41,427
-33,791
| -45% | -$447K | ﹤0.01% | 3960 |
|
|
2018
Q4 | $1.02M | Buy |
75,218
+25,321
| +51% | +$456K | ﹤0.01% | 3671 |
|
|
2018
Q3 | $1.11M | Sell |
49,897
-6,830
| -12% | -$144K | ﹤0.01% | 3746 |
|
|
2018
Q2 | $931K | Buy |
+56,727
| New | +$996K | ﹤0.01% | 3832 |
|
Other funds holding AMRX
TGA
RCMNY
UBS Group's AMRX Position: Q2 2026 in Review
UBS Group reduced its Amneal Pharmaceuticals (AMRX) stake by 47% in Q2 2026, selling an estimated $5.43M and leaving 444,400 shares worth $7.69M. The position accounts for ﹤0.01% of the portfolio, ranked #3738.
UBS Group first reported a position in AMRX in Q2 2018 and has held it in 33 quarters since. The position peaked at $181M in Q3 2024. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.
- UBS Group held 444,400 shares of Amneal Pharmaceuticals worth $7.69M as of Q2 2026.
- UBS Group sold 396,558 Amneal Pharmaceuticals shares in Q2 2026, an estimated $5.43M.
- Amneal Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3738 holding.
- UBS Group first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
- UBS Group's Amneal Pharmaceuticals position peaked at $181M in Q3 2024.
- 306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.